BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

VIDA Diagnostics Earns ISO 13485 and CE Certifications


9/19/2011 11:52:22 AM

CORALVILLE, Iowa, Sept. 19, 2011 /PRNewswire/ -- VIDA Diagnostics, a leading developer of quantitative pulmonary imaging software, announced today that the company has achieved International Organization for Standardization (ISO 13485) certification and CE certification for its flagship product, Apollo®. The CE certification permits VIDA to sell Apollo for clinical use in the European Economic Area (EEA) and Switzerland. Apollo currently has FDA 510(k) approval for clinical use in the U.S.

Apollo is VIDA's recently released, pulmonary image analysis solution designed to assess pulmonary disease objectively and repeatedly with unprecedented speed and accuracy. Used for the early detection, evaluation and aiding of treatment of pulmonary disease including COPD, emphysema, lung cancer, and asthma; VIDA's analysis methodology has been successfully tested in multiple academic and clinical trials.

"Receiving these certifications are significant milestones for VIDA Diagnostics in establishing high quality standards and generating a solid platform for commercialization in the worldwide market," stated Susan A. Wood, Ph.D., VIDA Diagnostics' President and Chief Executive Officer. "We are excited to expand the reach of VIDA solutions."

VIDA Diagnostics will be attending the European Respiratory Society 2011 Congress in Amsterdam, Netherlands, September 25-28, 2011.

About VIDA Diagnostics

VIDA Diagnostics is a leader in clinically-validated quantitative pulmonary analysis software for the early detection, evaluation and treatment of pulmonary disease including COPD, emphysema, lung cancer, and asthma. FDA approved and CE certified, VIDA's analysis methodology has been successfully tested in multiple academic, pulmonary device, and pharmaceutical clinical trials.

www.vidadiagnostics.com

SOURCE VIDA Diagnostics


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->